ArticleDrug design, development and therapy2026
Population Pharmacokinetics of Tiapride in Children and Adolescents with Tic Disorders: Leveraging Plasma and Saliva Concentration to Guide Individualized Dosing.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to develop population pharmacokinetic (PopPK) models of tiapride based on plasma and saliva concentration in pediatric patients with tic disorders (TD) and evaluate the feasibility of non-invasive therapeutic drug monitoring (TDM) for precision dosing. Methods: A prospective study was conducted in 38 TD patients aged 5-15 years. PopPK models of tiapride were sequentially developed using nonlinear mixed-effects modeling. Monte Carlo simulation was employed to optimize dosing regimens, and Bayesian maximum a posteriori (MAP) was applied to facilitate model-informed precision dosing (MIPD). The predictive performance of the established model was internally evaluated using saliva concentration. Results: The PopPK model of tiapride using plasma concentration was best described by a one-compartment structure model. The typical estimates of the absorption rate constant (Ka), plasma clearance (CL/F), and volume of distribution (V/F) were 0.219 h Conclusion: The PopPK models of tiapride enable MIPD in children and adolescents with TD and support saliva as a non-invasive matrix for TDM. Further prospective validation in independent pediatric cohorts is warranted before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.